新型口服抗凝药与创伤:美国创伤外科协会多中心前瞻性试验结果
该前瞻性观察性试验纳入16个创伤中心共1847例因创伤入院且正在服用阿司匹林、氯吡格雷、华法林、达比加群、利伐沙班或阿哌沙班的患者,比较颅内出血、颅内出血进展及死亡。服用新型口服抗凝药者颅内出血风险在单变量(24% vs 31%)和多变量分析(发生率比0.78,置信区间0.61-1.01,p=0.05)中均未增高。阿司匹林组颅内出血发生率最高(35%),风险发生率比1.27(置信区间1.13-1.43,p<0.001)。颅内出血进展发生率为17%,各组间无差异;死亡率为7%,各组间无显著差异。
要点
- 服用新型口服抗凝药的创伤患者颅内出血风险未高于其他药物组:单变量24% vs 31%,多变量发生率比0.78(置信区间0.61-1.01,p=0.05)。
- 阿司匹林组颅内出血发生率最高(35%),风险发生率比1.27(置信区间1.13-1.43,p<0.001),阿司匹林剂量为81 mg者占90%、325 mg者占10%。
- 颅内出血进展发生于17%的患者,各药物组间无差异。
- 研究死亡率为7%,单变量和多变量分析各组间均无显著差异。
- 纳入患者中50%服用抗血小板药,33%服用华法林,10%服用新型口服抗凝药,7%使用联合治疗或皮下制剂。
适用人群与场景
- 16个创伤中心收治的因创伤入院且正在服用阿司匹林、氯吡格雷、华法林、达比加群、利伐沙班或阿哌沙片的创伤患者。
- 纳入患者平均年龄74.9岁(标准差±13.8),46%为女性,77%为非西班牙裔白人,94%报告至少一种合并症。
- 99%为钝性创伤,中位损伤严重度评分为9(四分位距4-14)。
研究设计与关键结果
- 研究类型为前瞻性观察性试验,纳入16个创伤中心共1847例患者,入组时间为2013年7月至2015年6月。
- 新型口服抗凝药组颅内出血发生率24% vs 其他药物组31%,多变量分析发生率比0.78(置信区间0.61-1.01,p=0.05),未达统计学显著。
- 阿司匹林组颅内出血发生率35%,风险发生率比1.27(置信区间1.13-1.43,p<0.001),为所有药物中最高。
- 颅内出血进展发生于17%的患者,各药物组间无差异。
- 研究死亡率为7%,单变量和多变量分析各组间均无显著差异。
证据类型、等级与局限
- 证据类型为前瞻性观察性试验,证据等级为预后/流行病学研究,level III。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为服用新型口服抗凝药的创伤患者颅内出血、颅内出血进展或死亡风险并未增高。
- 阿司匹林组颅内出血发生率和风险最高(35%,发生率比1.27,置信区间1.13-1.43,p<0.001)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The number of anticoagulated trauma patients is increasing. Trauma patients on warfarin have been found to have poor outcomes, particularly after intracranial hemorrhage (ICH). However, the effect of novel oral anticoagulants (NOAs) on trauma outcomes is unknown. We hypothesized that patients on NOAs would have higher rates of ICH, ICH progression, and death compared with patients on traditional anticoagulant and antiplatelet agents.
METHODS: This was a prospective observational trial across 16 trauma centers. Inclusion criteria was any trauma patient admitted on aspirin, clopidogrel, warfarin, dabigatran, rivaroxaban, or apixaban. Demographic data, admission vital signs, mechanism of injury, injury severity scores, laboratory values, and interventions were collected. Outcomes included ICH, progression of ICH, and death.
RESULTS: A total of 1,847 patients were enrolled between July 2013 and June 2015. Mean age was 74.9 years (SD ± 13.8), 46% were female, 77% were non-Hispanic white. At least one comorbidity was reported in 94% of patients. Blunt trauma accounted for 99% of patients, and the median Injury Severity Score was 9 (interquartile range, 4-14). 50% of patients were on antiplatelet agents, 33% on warfarin, 10% on NOAs, and 7% on combination therapy or subcutaneous agents.Patients taking NOAs were not at higher risk for ICH on univariate (24% vs. 31%) or multivariate analysis (incidence rate ratio, 0.78; confidence interval 0.61-1.01, p = 0.05). Compared with all other agents, patients on aspirin (90%, 81 mg; 10%, 325 mg) had the highest rate (35%) and risk (incidence rate ratio, 1.27; confidence interval, 1.13-1.43; p < 0.001) of ICH. Progression of ICH occurred in 17% of patients and was not different between medication groups. Study mortality was 7% and was not significantly different between groups on univariate or multivariate analysis.
CONCLUSION: Patients on NOAs were not at higher risk for ICH, ICH progression, or death.
LEVEL OF EVIDENCE: Prognostic/epidemiologic study, level III.
参考来源
- Kobayashi L, Barmparas G, Bosarge P, et al. Novel oral anticoagulants and trauma: The results of a prospective American Association for the Surgery of Trauma Multi-Institutional Trial. J Trauma Acute Care Surg. 2017. PMID: 28431413. doi:10.1097/TA.0000000000001414
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。